Wells Fargo lowered the firm’s price target on Humana to $413 from $465 and keeps an Overweight rating on the shares. While EPS guidance for 2024 was “clearly disappointing,” it does appear to have embedded a fairly conservative set of assumptions, the firm says. Wells sees reasons to expect a modestly better rate environment in 2025 as industry appears headed for repricing cycle.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on HUM:
- Humana downgraded to Neutral from Overweight at Cantor Fitzgerald
- Humana price target lowered to $400 from $550 at Truist
- Tesla downgraded, Coinbase upgraded: Wall Street’s top analyst calls
- Humana price target lowered to $415 from $507 at RBC Capital
- Humana price target lowered to $430 from $550 at Stephens